pharma

Newswire

[ March 27, 2024 ] Snow Lake (NASDAQ: LTIM) Initiates 2024 Exploration Program at Engo Valley Uranium Project Mining & Metals
[ February 26, 2024 ] Snow Lake (NASDAQ: LITM)Transformational Acquisition of the Highly Prospective Engo Valley Uranium Project, Namibia Mining & Metals
[ February 13, 2024 ] Snow Lake (NASDAQ: LITM) Expands Its Lithium Portfolio with Mineral Claims near Kenora, Ontario Mining & Metals
[ January 16, 2024 ] Appia (OTC: APAAF) Reports 92,758 ppm (9.3%) TREO, 13,798 ppm MREO (1.38%) and 2,241 (.24%) ppm HREO over 2m Within the Total Weighted Average of 38,655 ppm (3.87%) TREO, 6,869 ppm (.69%) MREO, and 1,380 ppm (.14%) HREO Across 24m (EOH) Following the Reanalysis of Over-Limit Assay Results from PCH-RC-063 at the PCH Ionic Adsorption Clay Project in Goias, Brazil Mining & Metals
[ January 15, 2024 ] Appia (OTC: APAAF) Announces Significant Geochemical Critical REE Assay Results at Alces Lake Project, Saskatchewan, Canada Mining & Metals
[ January 12, 2024 ] Appia Receives Approval for 12 Additional Claim Blocks at Its PCH Rare Earths Ionic Adsorption Clay Project, Goias, Brazil Mining & Metals
[ January 12, 2024 ] Snow Lake Lithium (NASDAQ: LITM) CEO Update to Shareholders Mining & Metals
[ December 21, 2023 ] Snow Lake (NASDAQ: LITM) Expands Its Lithium Portfolio with Mineral Claims Next to the Tanco Mine Mining & Metals
[ December 18, 2023 ] Appia (OTC: APAAF) Announces Non-Brokered Flow-Through Private Placement Mining & Metals
[ December 13, 2023 ] Appia (OTC: APAAF) Announces Scandium and Cobalt Discovery at Its New Buriti Target at the PCH Project, Brazil; Reverse Circulation Drill Hole Returns 24 Metres of Mineralization Averaging 128 ppm Scandium Oxide, 272 ppm Total Cobalt Oxides and 2,106 ppm Total Rare Earth Oxides from Surface Mining & Metals

CEO Interview

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) Creating “blockbuster” potential drugs, from deuterium chemistry tech

March 14, 2019 admin Comments Off

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) Interview with Roger Tung, CEO discussing the company’s deuterium chemistry platform for creating new drugs which have superior properties—including enhanced clinical safety, tolerability […]

CytoDyn Inc. (OTC: CYDY) Monoclonal antibody for treating HIV and Cancer. Potential FDA approval for HIV in 2019

January 3, 2019 admin Comments Off

CytoDyn Inc. (OTC: CYDY) CEO Interview with Nader Pourhassan, Ph.D, discussing CytoDyn’s PRO140 monoclonal antibody therapy for HIV and cancer. The company is at a […]

Newsmakers

FSD Pharma Appoints Top GW Pharmaceuticals Executive, Rupert Haynes, as Chief Executive Officer

November 26, 2018 admin Comments Off

Management addition comes as FSD accelerates specialty cannabinoid pharmaceutical global expansion strategy TORONTO, Nov. 26, 2018 – FSD Pharma Inc. (“FSD Pharma” or “FSD”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today the appointment of […]

FSD Pharma (CSE: HUGE) (OTC: FSDDF) Investor Presentation by Dr. Raza Bokhari New Green Frontier Cannabis Investor Conference

November 21, 2018 admin Comments Off

FSD Pharma (CSE: HUGE) (OTC: FSDDF) Investor Presentation by CEO Dr. Raza Bokhari at the New Green Frontier Cannabis Investor Conference

Nexien BioPharma, Inc (OTC: NXEN) Developing a cannabinoid-based drug pipeline.

November 14, 2018 admin Comments Off

Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.

Newsmakers

Zoetis (NYSE: ZTS) to Expand Animal Vaccine Research and Manufacturing in Suzhou, China

April 26, 2018 admin Comments Off

SHANGHAI–Zoetis Inc. (NYSE: ZTS) today celebrated the start of construction on a combined global manufacturing and supply and research and development center in Suzhou, China, with a traditional groundbreaking ceremony. The new facility will focus […]